IMATINIB ACTAVIS GROUP 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

imatinib actavis group 100 mg

actavis group ptc ehf. - islanda - imatinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza

IMATINIB ACTAVIS GROUP 400 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

imatinib actavis group 400 mg

actavis group ptc ehf. - islanda - imatinibum - compr. film. - 400mg - alte antineoplazice inhibitori de protein-kinaza

LISINOPRIL ACTAVIS 5 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lisinopril actavis 5 mg

actavis group ptc ehf. - islanda - lisinoprilum - compr. - 5mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei

LISINOPRIL ACTAVIS 20 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lisinopril actavis 20 mg

actavis group ptc ehf. - islanda - lisinoprilum - compr. - 20mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei

LISINOPRIL ACTAVIS 10 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lisinopril actavis 10 mg

actavis group ptc ehf. - islanda - lisinoprilum - compr. - 10mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei

STURIBAN 0,1 mg/ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sturiban 0,1 mg/ml

actavis group ptc ehf. - islanda - bimatoprostum - pic. oft., sol. - 0,1mg/ml - antiglaucomatoase si miotice analogi de prostaglandine

STURIBAN 0,3 mg/ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sturiban 0,3 mg/ml

actavis group ptc ehf. - islanda - bimatoprostum - pic. oft., sol. - 0,3mg/ml - antiglaucomatoase si miotice analogi de prostaglandine

Meropenem Actavis pulbere pentru solutie injectabila/perfuzabila 1 g Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

meropenem actavis pulbere pentru solutie injectabila/perfuzabila 1 g

actavis group ptc ehf. - meropenemum - pulbere pentru solutie injectabila/perfuzabila - 1 g

Meropenem Actavis pulbere pentru solutie injectabila/perfuzabila 500 mg Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

meropenem actavis pulbere pentru solutie injectabila/perfuzabila 500 mg

actavis group ptc ehf. - meropenemum - pulbere pentru solutie injectabila/perfuzabila - 500 mg

Imatinib Actavis Uniunea Europeană - română - EMA (European Medicines Agency)

imatinib actavis

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.